Data presented at the ESMO Congress 2022
JB Bachet,1 C Pinto,2 G Bodoky,3 F Marti Marti,4 A Mitroshkin,5 E Choucair,6 M Fazilleau,6 A Sullivan,7 R Garcia-Carbonero,8 M Koopman9
1. Sorbonne Université, Service d’hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France; 2. Medical Oncology, Clinical Cancer Centre Azienda USL – IRCCS di Reggio Emilia – Viale Risorgimento, 80 42123 Reggio Emilia, Italy; 3. Dél-Pesti Centrumkórház Szent László Telephely Albert Flórián út 5–7 1097 Budapest, Hungary; 4. The Christie NHS Foundation Trust, Manchester, UK; 5. Klinikum Freudenstadt, akademisches Lehrkrankenhaus der Universität Tübingen, Karl-von-Hahn str. 120, 72250 Freudenstadt, Germany; 6. Global Medical and Patient Affairs Servier, Suresnes, France; 7. Servier Pharmaceuticals, Boston, MA, USA; 8. Hospital Universitario Doce de Octubre Imas12, UCM, Av. De Córdoba s/n, 28041 Madrid, Spain; 9. University Medical Centre Utrecht, Utrecht University Heidelberglaan 100 3584 CX Utrecht, the Netherlands.
back to top
Tumor shrinkage and disease control with preservation or improvement in quality of life are the primary treatment goals for patients with unresectable mCRC1
When not possible, emphasis lies in avoidance of rapid disease evolution, and prolonging survival1
Advances in mCRC treatment have now improved median overall survival to 30 months in clinical trials1
PROMETCO (NCT03935763) is the first international, prospective real-world study to investigate the continuum of care in the mCRC patient population, collecting data on all patients regardless of treatment or age
Aim: To present real-world treatment patterns for metastatic disease, up to fourth line, for the first 531 patients enrolled in the PROMETCO study, as of October 1, 2021
Inclusion criteria: Adult patients with two disease progressions since the first diagnosis of metastatic disease, suitable to receive subsequent treatment
mCRC, metastatic colorectal cancer.
1. Van Cutsem E, et al. Ann Oncol. 2016;27:1386–422.
back to top
Biomolecular status
Age and sex
ECOG PS
Disease characteristics
Baseline treatment/surgery
back to top
Definitions
First line
Second line
Third line
Fourth line
back to top
Preliminary data from the PROMETCO study provide a greater understanding of the population and key insights into the treatments received by patients with mCRC in clinical practice
In first and second line, most of the patients received CT doublet/triplet + anti-VEGF/EGFR. This is in line with treatment guidelines1
Maintenance and reintroduction were mainly represented in first line, whereas rechallenge was marginally higher in third and fourth lines, versus other lines
Sixty-eight percent of patients received FTD/TPI in third-line treatment, and 43% received regorafenib in fourth line. In-depth analysis is planned to better understand the third- and fourth-line treatment allocation (based on access to treatment options locally)
Median time between mCRC diagnosis and PROMETCO inclusion was 23 months, while median total treatment duration before inclusion was 13.3 months, therefore suggesting the use of treatment breaks in the real world
CT, chemotherapy; EGFR, epidermal growth factor receptor; FTD/TPI, trifluridine/tipiracil; mCRC, metastatic colorectal cancer; VEGF, vascular endothelial growth factor.
1. Van Cutsem E, et al. Ann Oncol. 2016;27:1386–422.
back to top